Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin in pediatric open heart surgery
NCT02527811Phase 4Unknown
- Sponsor
- Guangdong Techpool Bio-pharma
- Start
- Apr 2015
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ulinastatin in complex congenital heart disease (CCHD) (2 arms), sponsored by Guangdong Techpool Bio-pharma. Primary endpoint: Dynamic changes of arterial oxygen tension / inspired oxygen fraction ratio at 5 days. Status: unknown.
02
Drugs
ulinastatin
03
Conditions
complex congenital heart disease (CCHD)
Beyond the preview
Go deeper on NCT02527811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527811.